Fluralaner vs Sarolaner: Different Speeds and Durations

How Fast Each Active Ingredient Kills Parasites

Bravecto contains fluralaner, an isoxazoline compound that begins killing fleas within 2 hours of administration and achieves high efficacy within 8-12 hours. For tick control, fluralaner demonstrates rapid action, beginning to kill ticks within 12-24 hours. This quick action helps prevent transmission of tick-borne pathogens like Lyme disease and ehrlichiosis, which typically require 24-48 hours of tick attachment for disease transmission.

Regular Simparica contains sarolaner, also from the isoxazoline class, which starts killing fleas within 3 hours and ticks within 8 hours. While slightly slower than fluralaner for flea control, sarolaner’s tick-killing speed is comparable, maintaining the critical window needed to prevent disease transmission. Both active ingredients work by inhibiting the nervous system of insects and arachnids, causing paralysis and death.

Protection Duration Varies by Product

The duration differences between these medications stem from their distinct pharmacokinetic properties. Fluralaner maintains therapeutic blood levels for up to 12 weeks, providing sustained parasite-killing activity throughout this extended period. This extended half-life allows for quarterly dosing while maintaining consistent efficacy against new infestations.

Sarolaner in regular Simparica provides 35 days of protection, extending slightly beyond standard monthly treatments. Simparica Trio, while offering broader parasite coverage, provides only 30 days of protection against fleas and ticks, requiring strict monthly dosing to maintain continuous coverage without gaps.

Tick Species Coverage Shows Key Differences

Bravecto’s Variable Protection Periods by Tick Type

Bravecto’s protection duration varies depending on the specific tick species encountered. Against black-legged ticks, American dog ticks, brown dog ticks, and Asian longhorned ticks, the medication provides full 12-week protection. However, Lone Star tick protection specifically lasts only 8 weeks per dose, requiring more frequent administration in regions where this aggressive species is prevalent.

This variation in protection periods reflects the different susceptibility levels among tick species to fluralaner. The reduced duration against Lone Star ticks necessitates careful consideration of regional tick populations when determining dosing schedules, particularly in southeastern United States where this species is most common.

Simparica Covers 6 Tick Species for Full Month

Simparica provides consistent 35-day protection against six tick species: black-legged ticks, American dog ticks, brown dog ticks, Lone Star ticks, Gulf Coast ticks, and Asian longhorned ticks. This coverage includes the Gulf Coast tick, which Bravecto does not formally claim to control, making Simparica particularly valuable in coastal regions where this species occurs.

Recent comparative studies demonstrate Bravecto’s superior residual efficacy over extended periods. Research published in Parasites & Vectors showed that all dogs receiving Bravecto remained 100% tick-free at every 24-hour assessment throughout the study period, while Simparica Trio-treated dogs were never completely tick-free at any evaluation point, suggesting potential advantages for sustained protection.

Safety Differs for Young Dogs and Special Populations

Age and Weight Requirements Favor Simparica

Age requirements differ between these medications, with both regular Simparica and Bravecto approved for dogs 6 months and older. However, Simparica Trio offers more permissive age requirements, being approved for puppies as young as 8 weeks old. This earlier approval makes Simparica Trio particularly valuable for young puppies requiring parasite protection.

Weight requirements also favor the Simparica products, with both formulations safe for dogs weighing 2.8 pounds or more. Bravecto requires a minimum weight of 4.4 pounds, potentially limiting options for toy breeds and very small dogs. This weight difference, while seemingly minor, can be significant for owners of Chihuahuas, Yorkshire Terriers, and other diminutive breeds.

Breeding and Pregnant Dogs Have Different Restrictions

Reproductive safety profiles differ significantly between these medications. Bravecto has been evaluated for use in breeding, pregnant, and lactating dogs, though some adverse events have been reported following use in breeding females. This evaluation provides more data for reproductive animals compared to other options.

Both Simparica formulations carry warnings that their safety has not been established in breeding, pregnant, or lactating dogs. This limitation restricts their use in breeding programs and requires alternative parasite control strategies for pregnant or nursing females, potentially complicating parasite prevention in breeding operations.

Isoxazoline Class Carries Neurological Warnings

All three products carry FDA warnings regarding potential neurological effects associated with the isoxazoline drug class. These effects, including tremors, ataxia, and seizures, are reported as rare occurrences. However, dogs with pre-existing neurological conditions, particularly seizure disorders, may face increased risk.

Bravecto initially required no neurological warning during pre-approval testing, while other isoxazolines demonstrated such effects during initial clinical trials. The warning was later applied to all isoxazoline products as a class-wide precaution, despite varying individual safety profiles among different products.